http://www.regentherapeutics.com/regen

Consider a company with a market cap of around 10 million which could well in the future be generating revenue well in excess of that figure every year. Interested then read on and DYOR on Regen Therapeutics.

For some time now I have been a shareholder of RGT who have been working with a patented product Colostrinin as a treatment for Alzheimers. Tests so far would seem to indicate that it is a success and they are currently refining a pharmaceutical product.

Meantime they are also pushing forward on the nutraceutical front as tests have shown positive results in respect of mild cognitive disorders (memory loss etc). Further research is being carried out regarding other major illnesses. As at mid 2007 a launch is scheduled in the US for Q4 and there are rumours of an earlier launch in Australia possibly imminent based on the fact that adverts are already starting to appear see:- http://www.quantumevolution.com.au/oscommerce/index.php

They have also acquired a contract research organisation which should mean that research money for clinical trials that had previously been spent will now be kept inside the group.

February 2006 has seen Regen acquire the rights, following a feasibility study, in respect of other uses for a well known drug (Zolpidem) that has undergone phase 2 clinical trials where results are expected around August 2007. The new use relates to the positive effects that have been seen when treating stroke victims with the drug. There has been a lot of press interest which a web search should reveal.

An interview with the chairman (Percy Lomax) in the summer of 2004 talked of a nutraceutical product producing royalty payments of 10% on a possible 100 million sales per annum. The pharmaceutical version which also requires a licensing partner will if successful have projected sales of 1-5 billion again which would generate royalty payments to Regen. I leave you to contemplate just how high the share price would be if this were the case but suffice to say it will be many many times what it is now.

Acquisition (Oct 2004) of Guildford Clinical Pharmacology unit demonstrates not only that they are progressive and expanding but also thinking strategically for GCPUL being a research based company no doubt Regen can now keep such costs within the group whereas before testing had to be paid for elsewhere. This acquisition also means that they have revenue and are therefore no longer a "virtual" company.

A share issue in July 2007 means that they should now have funds in hand to take them through to cash generation. Hopefully this means we have seen the last of the issues excepting any used by way of acquiring profitable companies.

The North America link is an interesting one as perhaps in readiness for the launch of Colostrinin out there Regen set up an ADR programme which became effective in March 2005. ADR's ( American Depositary Receipts) are a way for US investors to buy shares in UK companies. In Regen's case one ADR is equivalent to 200 Regen UK shares so when an ADR is purhased the Bank of New York will buy the proportionate number of UK shares and convert them into ADR's for the investor. At present this is not a factor however with the launch of Colostrinin out there if successful it may mean that US investors will want to be involved in the company and that will have a direct positive impact on our share price. In the US Colostrum (from which Colostrinin is produced )is already a recognised and popular health product and so demand should be good.

So all in all exciting times ahead. There can be few shares around that offer the potential of this one although as always DYOR and good luck with your investments whatever you decide here.

Just got back and slightly surprised to see such a small movement in the SP. I havent yet read what has been released but here goes for a resume of the AGM.

Firstly and on a personal level most importantly I have now actually held Colostrinin tablets in my hand. Suddenly after all the research, rumours and speculation I have actually seen and held different versions of the tablet, these being: the 100mg version that Metagenics are using to approach the retail market in the US currently packaged as NG550; a 200mg capsule for feline trials; a 600mg capsule for canine trials and a chocolate flavoured human version. Whilst there was much other positive news at the meeting for me to actually see the product was very reassuring.

Moving on. The meeting was well attended with most of Regen there including the scientists Andrew Sutton and Ralf Claus who are behind the Zolpidem story. Peter Garrod was there and Tigran as well as a number of PIs and various others amongst whom were various people connected with financial institutions.

CLN Nutra

This all seemed very positive with the long awaited news that Tox and Gmp are now sorted. Launch seems pretty definite for October. The question was asked about when we might actually see revenue and whilst this was not definitively answered because of being price sensitive information we did glean that there should be revenue coming from the manufacturing side on delivery. So whilst we probably wont know how much until we see the year end results I am expecting that perhaps in September the tap should begin to turn on in respect of first funds coming in from the nutra. Royalties will obviously follow based on sales.

Discussions are ongoing for deals elsewhere and I would not be surprised to hear more in that respect fairly soon.

There does seem to be a possible angle for use of CLN as a food additive and Regen have been approached with different ideas. I could not nail down whether this was in the immediate pipeline as they are so excited about the imminent launch of Colostrinin nutra and the results of Zolpidem that these were definitely the main areas of focus.


Pets nutra.

Trials are to begin on 1st June with results probably coming out around November. These are being carried out by Nick Mills who has a large vetinary practice in the South East and has been keen to research this for some time as I remember his name coming up in the past

Zolpidem.

We are advised that trials are going well and that the spray is definitely showing positive results. The spray is quite key as it shows faster results and by virtue of different delivery method adds further weight to the use patent. They are working with Novadel for spray delivery

Good news that the first use patent has now been granted in South Africa and is in the process elsewhere. This should be good news for those concerned about ownership.

The use patent is something I had not fully understood previously and I queried at length today just to try and be sure Id got it right as I had been hung up on the 5mg issue. Zolpidem is currently a 10 mg sleeping tablet. Regen know it works in terms of the Lazarus effect etc in many cases but needed to lose the sedative hence looking at a lower dosage.

They have sought to get a patent to prevent others producing doses of 5mg or less as they could argue they were just trying to muscle in on their area of market for at that level there is no sedative effect so why would someone want to produce it for anything other than the are Regen are researching. However my understanding today is that the use patent does not relate just to the lower dosage it relates to use at whatever dosage. So if Regen can lose the sedative effect in some way at a particular dosage then someone else could not mirror that dosage for the same use.

It was reported that there have been no safety issues in the trials so far.

Certainly speaking with Andrew Sutton he is as excited now about the effects of Zolpidem as he was last time I saw him and despite his wealth of experience in this field he is resolute about the fact that this is the biggest potential market he has ever seen. Although of course whilst he might like to think that everything is going well they are carrying out the trials for a reason and once the massive volume of data is in it will probably take a month or so to assimilate the results hence if trials are completed by end June I would therefore expect results around end July/ beginning of August. Note that the Sciencom deal is based around Zolpidem showing positive results at trial whereupon the payment will be made in Regen shares so they will be keen to get to this stage whilst the share price is still depressed as it means they will get more shares for their money.

CLN Pharma

A lot of work has been going on in this area and full results are expected in Q4 of this year. They have identified a number of peptides which have displayed positive properties in different areas and once all data is in they would look to move forward with preclinical candidates and possible licensing deals. Again Percy seemed quite excited about this area of research but the more imminent news on Zolpidem and the nutra launch overshadowed it a little.

GCPL

Order book down on this time last year although I got the impression that there might not be a huge variation in actual sales.


Funding

They will need some funding before break even but are exploring possibilities. There were a number of financial questions from 2 fairly clued up investors. To one PL said that if there were a way of raising the funds without going to the market then he would do it as like us he does not like the idea of dilution.

I did ask about consolidation and he said that his advisors had said that it was not something they would recommend at the time of the last issue. He did appreciate the concerns of the smaller investor and any such move would be made with investors best interests at heart.

There was a question relating I believe to the need for resolution 8 which I have to confess I got a little lost in the answer. I think they were basically saying that the earlier authority gave them the right to issue shares but certain rules mean they were limited in the amount they could issue in one block without coming to the market and this resolution overcame it. Bearing in mind that there were institutions represented there today I did wonder whether this might have been geared up as a way for them to buy in a big block outside of the ordinary market. I am sure there are others who will understand the intricacies of the rules a little better to shed light on this point.

When asking about funding etc I did make the point that my interpretation of the accounts was that current cash should last until Mid July. This was not allowing for any GCPL revenue and if the nutra product were to be paid in part for manufacture prior to launch then this should mean that they ought not to have to raise too much money this year for working costs. This point was not disputed but not confirmed either. I came away with the impression that they will have to raise funds prior to the end of the year but as for whether this will be an issue in normal sense or an institutional investment I could not say.

I think that has covered everything. All in all a positive meeting with a general veiled optimism about everyone connected with the company. Both Peter Garrod and Tigran seemed very happy with their investments.

Certainly this is going to be an exciting few months with lots happening which I have roughly timelined as:-

1 June Start of vetinary trials
End June Zolpidem trials end
End July/ Begin Aug - Zolpidem results
October Nutra Launch
Oct Dec Results of research in for CLN peptides & assessment of preclinical candidates
Nov - Vetinary trial results

During this time we could also hear about further nutra deals and if Zolpidem results are very positive then perhaps a deal there too.

As always, posted in good faith and to the best of my recollection and interpretation.

It was good to see a bigger turn out today and six of us had a pleasant lunch afterwards. We did not crack open the champagne today, sticking to beer and wine but hopefully next time.

Gantenbrink - thank you for such an excellent and informative synopsis of the day.

more positive news today. marketing and development leading to a good end to this year..

watcher

BE VERY CAREFUL WITH THIS ONE, I HAVE HAD IT ON MY WATCH SCREEN FOR AGES!

CHECK THE TRADING RANGE FOR THE PAST YEAR IT WILL TAKE A BOMB FOR IT TO BREAK OUT OF THAT RANGE.

I dont think its going anywhere--I trust I AM WRONG FOR THE LONG TERM HOLDER'S SAKES.

Every range is one day broken David10B - As holders we just think (and hope) it will be in the right direction.

I trust this is true for all holders queen.

Good luck, but please remember what took this to 2p a while back and how quick the bottom fell out.

A rather uninspirering day chaps-- a what!

Interesting- yesterday we heard that Regen and Metagenics appeared together promoting Colostinin at a conference in Australia sponsored by Metagenics associate company in Australia Health World. Today it seem from the link below that Metagenics Australian website is promoting Colostrinin in their "shop" section when so far the only license granted is in the US. Hopefully there is more news on the horizon:-
https://www.metagenics.com.au/shop/index.cfm?fuseaction=item&id=745

BE CAREFUL OF THE MANAGEMENT HERE!

why david

Look at the history. Check it carefully.

What's your agenda here David? You've popped up from nowhere giving an extremely one-sided view in mini-soundbites and it would be interesting for longer-term posters to this thread to know why.

No Adgenda, does one have to always have one?

Just honest comments which a rewad of the compny's histroy, cashs calls share in circulation etc will substantial.

Seems to me this company has been trying to tread water for years but is slowly sinking. I dont mean it will go bust but it should be taken over as the products are good.

That said the management lack direction.

Fair enough, thanks for your response. The products are good which is why holders have faith.

jJaguar cars are great too, but you have to get the to the punters

queen1

Do you know anything about David...if not may I suggest you do some homework on this individual, because if you do you will find out that he is very unpleasant .

On ADVFN he goes under the nickname of 10JimB and Jim_ Bentley Davis.

Good luck with RGT.

What A LOAD OF RUBBISH FORM A DISGRUNTLED UNFORTUNATE COH SHARE OWNER WHO SIMPLY COULD NOT TAKE THE EXPOSURE I GAVE HIS PET SHARE!

What a child he should be banned from all financial BBs.

Queen1 please take up the little boy's offer and do you homeworks on me, send me an email and if your are ever down in Plymstock drop by, especially if your any good at building.

BMW WHEN ARE YOU GOING TO GROW UP?

I read them all and only post here

now now you two..lets keep to the subject in hand..it seems to me that promotional exposure can only help the s.p. looking at company products and development so far.

watcher

Thanks all - I have my own "idiot" who seems to follow me around at the moment (the latest chapter in the saga is currently running on the CEN thread) so I'm happy to keep out of another one. It would be good though David if your posts could be balanced otherwise their worth may be diminished.

Good luck to all holders anyway!

queen1

Don't say I did'nt warn you.

Good luck.